Prognostic significance of tumor-infiltrating CD8+ or CD3+ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer

Chinese Medical Journal

Volumn 128, Issue 1, 2015, Pages 105-110

  Tian, Chun Tao ^a   Lu, Shi Xin ^a,b   Fan, Qing Xia ^a   Zhang, Wei Jie ^a   Jiao, Shun Chang ^c   Zhao, Xiao ^c   Wu, Zhi Yong ^c   Sun, Liang ^d   Wang, Liu Xing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c Chinese Peoples Liberation Army General Hospital   (China)

^d ZHENGZHOU UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Immunological parameters; Non small cell lung cancer; Prognostic factors

Indexed keywords

INTERLEUKIN 2; CD3 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; VERY ELDERLY; IMMUNOLOGY; LUNG TUMOR; METABOLISM; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; PROGNOSIS;

EID: 84930721919     PISSN: 03666999     EISSN: 25425641     Source Type: Journal    
DOI: 10.4103/0366-6999.147828     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC lung cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
3. Dalgleish AG, O’Byrne K. Inflammation and cancer: The role of the immune response and angiogenesis. Cancer Treat Res 2006;130:1-38.
4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
5. Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP. Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer 2002;36:17-25.
6. Yoshino I, Yano T, Murata M, Ishida T, Sugimachi K, Kimura G, et al. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 1992;52:775-81.
7. Gong F. Medical Immunology. Beijing: Science Publishing Company; 2008. p. 102-19.
8. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003;94:1003-9.
9. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008;113:1387-95.
10. Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007;98:1424-30.
11. UICC. TNM Classification of Malignant Tumors. 5th ed. New York: Wiley; 1997. p. 93-7.
12. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological Typing of Lung and Pleural Tumour, International Histological Classification of Tumours. 3rd ed. Berlin, Heidelberg, New York: Springer; 1999.
13. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993;72:3641-7.
14. Kuo SH, Chang DB, Lee YC, Lee YT, Luh KT. Tumour-infiltrating lymphocytes in non-small cell lung cancer are activated T lymphocytes. Respirology 1998;3:55-9.
15. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecol Oncol 2012;124:192-8.
16. Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 2002;140:320-8.
17. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
18. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007;58:267-74.
19. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macrì L, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009;87:365-71.
20. Trojan A, Urosevic M, Dummer R, Giger R, Weder W, Stahel RA. Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer. Lung Cancer 2004;44:143-7.
21. Törmänen-Näpänkangas U, Soini Y, Pääkkö P. High number of tumour-infiltrating lymphocytes is associated with apoptosis in non-small cell lung carcinoma. APMIS 2001;109:525-32.
22. Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund LT. The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. APMIS 2010;118:371-82.
23. Karagöz B, Bilgi O, Gümüs M, Erikçi AA, Sayan O, Türken O, et al. CD8+ CD28- cells and CD4+ CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol 2010;27:29-33.
24. Kasprzak A, Olejniczak K, Przybyszewska W, Zabel M. Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol (Warsz) 2007;66:159-66.
25. Neuner A, Schindel M, Wildenberg U, Muley T, Lahm H, Fischer JR. Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer 2002;101:287-92.